

# Overview of Panic and Social Anxiety Disorders

Herman G. M. Westenberg, Ph.D., and Michael R. Liebowitz, M.D.

Panic disorder and social anxiety disorder are often-overlooked but debilitating disorders that share some common symptoms and treatments. Patients with panic disorder experience unexpected panic attacks and then worry about having more attacks. Those with social anxiety disorder fear doing or saying something embarrassing in social situations. The prevalence of these conditions is about 3% for panic disorder and 13% for social anxiety disorder in the United States and is higher in women than in men. Both disorders are thought to have a familial link and to be related to dysregulation of neurotransmitter systems. Panic and social anxiety disorders are often comorbid with other psychiatric disorders. Medication treatment and/or cognitive-behavioral therapy might need to be continued over the long term to prevent relapse. *(J Clin Psychiatry 2004;65[suppl 14]:22–26)*

**A**lthough anxiety is experienced by everyone and, at appropriate levels, can be beneficial, excess anxiety that interferes with functioning may qualify as an illness such as panic disorder or social anxiety disorder. These disorders, which share some symptoms and are improved by several of the same treatments, are often underdiagnosed.

## PRESENTATION, PREVALENCE, AND COMORBIDITY

Panic disorder is the occurrence of unexpected panic attacks and the consequent worry of having more attacks or experiencing mental, physical, or social impairment related to the attacks, which may alter behavior. During a panic attack, patients experience sudden physical or emotional symptoms, such as chest pain, shortness of breath, hot flushes or chills, nausea, fear of going crazy, and fear of dying, that peak within 10 minutes. Panic disorder is commonly accompanied by agoraphobia. Patients with agoraphobia avoid or experience great distress and/or need a companion during situations or in places in which they fear being embarrassed or unable to escape or get help if a panic attack occurs.

---

*From the Department of Psychiatry, University Medical Centre, Utrecht, the Netherlands (Dr. Westenberg), and the Anxiety Disorders Program, New York State Psychiatric Institute, New York, N.Y. (Dr. Liebowitz).*

*This article is derived from the proceedings of the 6th International Obsessive-Compulsive Disorder Conference "Beyond Refractory Obsessions and Anxiety States: Toward Remission," which was held November 13–15, 2003, in Lanzarote, Spain, and supported by an unrestricted educational grant from Solvay Pharmaceuticals.*

*Corresponding author and reprints: Herman G. M. Westenberg, Ph.D., University Hospital Utrecht, Department of Psychiatry, A 01.126, P.O. Box 85500, 3508 GA Utrecht, the Netherlands (e-mail: h.g.m.westenberg@azu.nl).*

Social anxiety disorder is the fear of doing or saying something embarrassing or humiliating in social situations. Patients with social anxiety often isolate themselves from or endure social interaction with great distress and exhibit physical symptoms such as blushing and tremor. The 2 subtypes of social anxiety disorder are generalized and non-generalized. Patients with the generalized form fear most social situations, but patients with the nongeneralized form fear specific social situations, such as public speaking.

Panic and social anxiety disorders may cause social, occupational, and academic impairment. For example, because these patients fear a panic attack or social scrutiny by others, they may stay at home and suffer isolation from friends, financial loss from missed work, or lower grades from missed school. The impairments associated with these disorders often arise during the teenage years to the mid-30s—when educational, interpersonal, and occupational development is particularly important.

In the United States, the rate of lifetime diagnosis was found to be 3% for panic disorder (about 71% of those diagnosed were women and 29% men)<sup>1</sup> and 13% for social anxiety disorder (with a rate of 16% in women and 11% in men).<sup>2</sup> In Europe, the 12-month prevalence was 0.8% for panic disorder and only 1.1% for social anxiety disorder, and all anxiety disorders were 2 to 3 times more common in women than men.<sup>3</sup>

In a study of comorbidity in 360 patients with panic disorder, current comorbid conditions included major depressive disorder (23%), generalized anxiety disorder (16%), social anxiety disorder (15%), and obsessive-compulsive disorder (7%).<sup>4</sup> Substance abuse may be comorbid in about 10% to 20% of patients with panic-related anxiety disorders.<sup>5</sup> In the National Comorbidity Survey,<sup>6</sup> 56% of the patients who had panic disorder had a lifetime history of major depressive disorder. The survey<sup>2</sup> also showed that 81% of patients with social anxiety disorder had another psy-

chiatric condition such as another anxiety disorder (57%), major depressive disorder (37%), alcohol dependence (23%), and drug dependence (15%). Comorbid conditions, especially alcohol or drug dependence, can mask panic or social anxiety disorder. For example, patients with social anxiety may self-medicate with alcohol to ease nervousness before social situations.

## ETIOLOGY

Both panic and social anxiety disorders appear to have a familial link. In a meta-analysis<sup>7</sup> of family and twin studies, first-degree relatives of patients with panic disorder were at greater risk for the disorder than first-degree relatives of controls (10% vs. 2%); genetics appeared to account for 48% of the contribution to panic disorder. Similarly, first-degree relatives of patients with generalized social anxiety have been found to be substantially more likely to have social anxiety than relatives of controls<sup>8</sup> or relatives of patients with specific social anxiety.<sup>9</sup>

Research on the neurobiology of panic disorder has implicated both serotonin and norepinephrine dysregulations. Patients with panic disorder are more sensitive than controls to administration of  $\alpha_2$ -adrenoceptor agonists<sup>10</sup> and antagonists,<sup>11</sup> and they have a markedly elevated 3-methoxy-4-hydroxyphenylglycol (MHPG) volatility, which normalizes after fluoxetine treatment.<sup>12</sup> On the other hand, the selective norepinephrine reuptake inhibitor maprotiline is not effective in treating patients with panic disorder,<sup>13</sup> whereas the efficacy of imipramine, a mixed serotonin/norepinephrine reuptake inhibitor, correlates with the plasma level of the parent compound but not with its major metabolite, desipramine, which has predominantly norepinephrine reuptake properties.<sup>14</sup> Serotonin receptor agonists may cause anxiety and greater increases in cortisol or prolactin levels in people with panic disorder than in controls.<sup>15</sup> Selective serotonin reuptake inhibitors (SSRIs), on the other hand, are among the agents that most effectively reduce panic symptoms. Direct evidence for the role of serotonin was recently presented by Neumeister et al.,<sup>16</sup> who reported a reduced density of the 5-HT<sub>1A</sub> receptor in patients with panic disorder. Benzodiazepine receptors have been implicated by findings that agonists such as alprazolam and clonazepam are highly effective in reducing panic and that antagonists may cause panic in patients with panic disorder but not in controls.<sup>17</sup> Neuropeptide cholecystokinin receptor agonists are more likely to result in panic attacks in patients with panic disorder than in controls,<sup>18</sup> while antagonists may reduce the effect.<sup>19</sup> Finally, carbon dioxide<sup>20</sup> and lactate<sup>21</sup> are also more likely to induce panic symptoms in patients with panic disorder than in controls.

In social anxiety disorder, the neurobiology of the generalized form versus that of the specific form differs. Specific social anxiety disorder is more strongly associated

with autonomic nervous system dysregulations because  $\beta$ -blockers, which may reduce autonomic symptoms of social anxiety, appear to be effective for only the specific form.<sup>22,23</sup> Also, patients with the specific subtype had greater heart rate acceleration during a public speaking test than patients with the generalized subtype.<sup>24</sup>

Generalized social anxiety disorder is thought to be influenced largely by dopamine and serotonin function. The role of dopamine has been implicated by a variety of sources. Neuroleptics have been shown to induce social anxiety disorder when given to certain patient groups.<sup>25</sup> Also, social anxiety is more prevalent in patients with Parkinson's disease than in the general population<sup>26</sup>; Parkinson's disease is associated with low levels of dopamine in the striatum.<sup>27</sup> And social anxiety shares characteristics with detached personality,<sup>28</sup> which is associated with a low level of the dopamine-2 receptor.<sup>29</sup> Dopamine transporter binding density may be different in the basal ganglia of patients than controls; some findings suggest a lower rate<sup>30</sup> and others, a higher rate (H. Stevens, Ph.D.; F. van Veen, M.D.; N. J. A. van der Wee, M.D.; et al., manuscript submitted). These findings suggest the involvement of dopamine in the pathophysiology of social anxiety, but the precise mechanism is still to be determined.

The idea that serotonin plays a role in social anxiety disorder comes from several findings. Long-term treatment with SSRIs may increase the sociability of healthy controls,<sup>31</sup> and increased serotonin availability may speed recognition of social cues such as facial expressions.<sup>32</sup> Also, cortisol response to partial serotonin receptor agonists may be greater in patients with social anxiety disorder than controls.<sup>33</sup> Further, the long allele of the serotonin transporter promoter region 44 base pair deletion/insertion polymorphism may be associated with social anxiety disorder.<sup>34</sup> Finally, a study found that patients with social anxiety disorder had greater serotonin transporter binding density in the thalamus and right orbital frontal cortex than did healthy controls (H. Stevens, Ph.D.; F. van Veen, M.D.; N. J. A. van der Wee, M.D.; et al., manuscript submitted).

## TREATMENT

Selection of a single treatment or a combination of treatments should be influenced by the possibility for drug interactions and the presence of comorbid conditions that may be affected.

### Antidepressants

SSRIs are first-line therapy for panic and social anxiety disorders. The SSRIs found efficacious in panic disorder are citalopram,<sup>35</sup> fluoxetine,<sup>36</sup> fluvoxamine,<sup>37</sup> paroxetine,<sup>38</sup> and sertraline.<sup>39</sup> For social anxiety disorder, fluoxetine may have little effect,<sup>40</sup> but fluvoxamine,<sup>41</sup> paroxetine,<sup>42</sup> and sertraline<sup>43</sup> have been found efficacious. Physicians

should tell patients that the therapeutic effect may take 2 to 3 weeks to be reached.

Tricyclic antidepressants (TCAs) may improve symptoms of panic disorder and prevent relapse.<sup>44</sup> Clomipramine may be more efficacious than desipramine<sup>45</sup> and imipramine<sup>46</sup> for panic. In social anxiety disorder, imipramine—the only TCA studied—had little effect in a small open trial.<sup>47</sup> Many patients may find TCA side effects intolerable.

Overall, the monoamine oxidase inhibitors (MAOIs) have good evidence of efficacy in panic and social anxiety disorders. Phenelzine may improve panic and social anxiety disorder.<sup>22</sup> Tranylcypromine may be effective for social anxiety.<sup>48</sup> Moclobemide has been found as effective as the TCA clomipramine<sup>49</sup> and the SSRI fluoxetine<sup>50</sup> for panic disorder but has mostly poor results for social anxiety disorder.<sup>51,52</sup> MAOI side effects may outweigh the benefits.

Venlafaxine has shown promise for alleviating panic and social anxiety symptoms in small trials.<sup>53,54</sup> Studies<sup>55,56</sup> of bupropion in panic disorder show mixed results. In the single published study<sup>57</sup> of bupropion in social anxiety disorder, 5 of the 10 patients responded.

### Anxiolytics

Benzodiazepines, the classic anxiolytics, often improve panic and social anxiety disorders. In controlled studies,<sup>58,59</sup> clonazepam substantially reduced symptoms of both disorders. Alprazolam appears effective in panic disorder.<sup>58</sup> However, in the only controlled trial<sup>60</sup> of alprazolam in social anxiety disorder, the agent was not significantly more effective than placebo, possibly because both treatment groups included self-exposure, which may be effective alone. Because some patients may abuse benzodiazepines, these agents may be best used in patients without comorbid substance abuse. The anxiolytic buspirone may not be more effective than placebo for either panic or social anxiety disorder.<sup>61,62</sup>

### Anticonvulsants

The few studies of anticonvulsants in panic and social anxiety disorder have shown some efficacy. In a placebo-controlled trial<sup>63</sup> of gabapentin in panic disorder, symptoms were substantially reduced in only the severely ill patients. In a social anxiety disorder study,<sup>64</sup> the entire gabapentin-treated group experienced significantly greater improvement than the placebo group, but scores remained high after 14 weeks of treatment. Pregabalin<sup>65</sup> and valproic acid<sup>66,67</sup> have shown promise in both disorders in unpublished or open trials. A possible drawback of anticonvulsants is daytime sedation.

### β-Blockers

One trial<sup>68</sup> of propranolol in panic disorder found the agent effective, but most other trials<sup>69,70</sup> have shown no

significant improvement in panic. For example, in one study,<sup>70</sup> propranolol given prior to lactate infusions in panic patients lowered heart rate but did not block induced panic symptom. In social anxiety, although atenolol was not significantly more effective than placebo in 74 patients, 76% of whom had the generalized subtype,<sup>22</sup> β-blockers may relieve specific social anxiety associated with public performance.<sup>23</sup>

### Cognitive-Behavioral Therapy

A large body of research supports the efficacy of cognitive-behavioral therapy (CBT) in panic and social anxiety disorders, although whether CBT is as effective as pharmacotherapy remains unclear. In a meta-analysis<sup>71</sup> of panic disorder studies, improvements were greater with CBT alone than with pharmacotherapy alone or CBT and pharmacotherapy, a finding that has been controversial.<sup>72</sup> In a meta-analysis<sup>73</sup> of social anxiety treatment studies, CBT produced much greater improvement than placebo or a waiting list condition, and the benefits of CBT continued after discontinuation. More comparisons of CBT with efficacious medication are needed.

## CONCLUSION

Because panic and social anxiety disorders cause substantial impairment, physicians must be aware of the symptoms and comorbid conditions that may point to the presence of these disorders. Patients should generally receive an effective medication such as an SSRI or a benzodiazepine; CBT may also benefit patients, especially those who are taking medication but have residual symptoms. Treatments might need to be continued over the long term to prevent relapse.

*Drug names:* alprazolam (Xanax and others), atenolol (Tenormin and others), bupropion (Wellbutrin and others), buspirone (BuSpar and others), citalopram (Celexa), clomipramine (Anafranil and others), clonazepam (Klonopin and others), desipramine (Norpramin and others), fluoxetine (Prozac and others), gabapentin (Neurontin and others), imipramine (Tofranil and others), paroxetine (Paxil and others), phenelzine (Nardil), propranolol (Inderal, Innopran XL, and others), sertraline (Zoloft), tranylcypromine (Parnate), valproic acid (Depakene, Myproic Acid, and others), venlafaxine (Effexor).

*Disclosure of off-label usage:* The authors have determined that, to the best of their knowledge, bupropion, desipramine, paroxetine, valproic acid, venlafaxine, and maprotiline are not approved by the U.S. Food and Drug Administration for the treatment of panic disorder; atenolol, citalopram, gabapentin, tranylcypromine, and pregabalin are not approved for the treatment of social anxiety disorder; and alprazolam, buspirone, clomipramine, clonazepam, fluoxetine, imipramine, phenelzine, propranolol, fluvoxamine, and moclobemide are not approved for the treatment of panic disorder or social anxiety disorder.

## REFERENCES

1. Sheikh JI, Leskin GA, Klein DF. Gender differences in panic disorder: findings from the National Comorbidity Survey. *Am J Psychiatry* 2002;

- 159:55–58
2. Magee WJ, Eaton WW, Wittchen H-U, et al. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. *Arch Gen Psychiatry* 1996;53:159–168
  3. Bryson H, for the ESEMeD Scientific Committee. Impact of anxiety disorders within Europe: data from the European Survey of the Epidemiology of Mental Disorders (ESEMeD). *World J Biol Psychiatry* 2004;5(suppl 1):132. Available at: <http://www.wfsbp.org/get/2395367356>. Accessed May 17, 2004
  4. Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. *J Abnorm Psychol* 2001;110:585–599
  5. Cox BJ, Norton GR, Swinson RP, et al. Substance abuse and panic-related anxiety: a critical review. *Behav Res Ther* 1990;28:385–393
  6. Kessler RC, Stang PE, Wittchen H-U, et al. Lifetime panic-depression comorbidity in the National Comorbidity Survey. *Arch Gen Psychiatry* 1998;55:801–808
  7. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am J Psychiatry* 2001;158:1568–1578
  8. Stein MB, Chartier MJ, Hazen AL, et al. A direct-interview family study of generalized social phobia. *Am J Psychiatry* 1998;155:90–97
  9. Mannuzza S, Schneier FR, Chapman TF, et al. Generalized social phobia: reliability and validity. *Arch Gen Psychiatry* 1995;52:230–237
  10. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. *Arch Gen Psychiatry* 1986;43:1042–1054
  11. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. *Arch Gen Psychiatry* 1984;41:751–763
  12. Coplan JD, Papp LA, Pine D, et al. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. *Arch Gen Psychiatry* 1997;54:643–648
  13. Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. *Int Clin Psychopharmacol* 1988;3:59–74
  14. Mavissakalian MR, Perel JM. Imipramine dose-response relationship in panic disorder with agoraphobia: preliminary findings. *Arch Gen Psychiatry* 1989;46:127–131
  15. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. *Psychiatry Res* 1989;28:295–306
  16. Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin 1A receptor binding in panic disorder. *J Neurosci* 2004;24:589–591
  17. Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. *Arch Gen Psychiatry* 1990;47:917–925
  18. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. *Arch Gen Psychiatry* 1991;48:603–610
  19. Bradwejn J, Koszycki D, Couetoux du Tertre A, et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. *Arch Gen Psychiatry* 1994;51:486–493
  20. Gorman JM, Papp LA, Coplan JD, et al. Anxiogenic effects of CO<sub>2</sub> and hyperventilation in patients with panic disorder. *Am J Psychiatry* 1994;151:547–553
  21. Balon R, Pohl R, Yeragani VK, et al. Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. *Psychiatry Res* 1988;23:153–160
  22. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. *Arch Gen Psychiatry* 1992;49:290–300
  23. James IM, Griffith DN, Pearson RM, et al. Effect of oxprenolol on stage-fright in musicians. *Lancet* 1977;2:952–954
  24. Heimberg RG, Hope DA, Dodge CS, et al. DSM-III-R subtypes of social phobia: comparison of generalized social phobics and public speaking phobics. *J Nerv Ment Dis* 1990;178:172–179
  25. Pallanti S, Quercioli L, Rossi A, et al. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. *J Clin Psychiatry* 1999;60:819–823
  26. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 1996;8:383–392
  27. Bergman H, Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. *Mov Disord* 2002;17(suppl 3):S28–S40
  28. Schneier FR, Blanco C, Antia SX, et al. The social anxiety spectrum. *Psychiatr Clin North Am* 2002;25:757–774
  29. Laakso A, Vilkmann H, Kajander J, et al. Prediction of detached personality in healthy subjects by low dopamine transporter binding. *Am J Psychiatry* 2000;157:290–292
  30. Tiihonen J, Kuikka J, Bergström K, et al. Dopamine reuptake site densities in patients with social phobia. *Am J Psychiatry* 1997;154:239–242
  31. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. *Am J Psychiatry* 1998;155:373–379
  32. Harmer CJ, Bhagwagar Z, Perrett DI, et al. Acute SSRI administration affects the processing of social cues in healthy volunteers. *Neuropsychopharmacology* 2003;28:148–152
  33. Hollander E, Kwon J, Weiller F, et al. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. *Psychiatry Res* 1988;79:213–217
  34. Oh KS, Yoon HK, Lee MS, et al. A polymorphism study of serotonin transporter gene (5-HTTLPR) in Korean social phobia patients. *Eur Neuropsychopharmacol* 2003;13(suppl 4):S366
  35. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. *J Clin Psychiatry* 1998;59:528–534
  36. Michelson D, Pollack M, Lydiard RB, et al, for the Fluoxetine Panic Disorder Study Group. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. *Br J Psychiatry* 1999;174:213–218
  37. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. *Psychiatry Res* 2001;103:1–14
  38. Lecrubier Y, Judge R, and the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. *Acta Psychiatr Scand* 1997;95:153–160
  39. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. *Acta Psychiatr Scand* 2001;104:289–298
  40. Kobak KA, Greist JH, Jefferson JW, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. *J Clin Psychopharmacol* 2002;22:257–262
  41. Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. *Int J Neuropsychopharmacol* 2003;63:317–323
  42. Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. *J Clin Psychiatry* 2004;65:222–229
  43. Liebowitz MR, DeMartinis NA, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. *J Clin Psychiatry* 2003;64:785–792
  44. Mavissakalian MR, Perel JM. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. *Arch Gen Psychiatry* 1999;56:821–827
  45. Sasson Y, Iancu I, Fux M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. *Eur Neuropsychopharmacol* 1999;9:191–196
  46. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. *J Clin Psychopharmacol* 1992;12:251–261
  47. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. *J Clin Psychopharmacol* 1998;18:132–135
  48. Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. *J Clin Psychopharmacol* 1988;8:279–283
  49. Krüger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. *Eur Arch Psychiatry Clin Neurosci* 1999;249(suppl 1):S19–S24
  50. Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. *Br J Psychiatry* 1999;174:205–212
  51. Stein DJ, Cameron A, Amrein R, et al, for the Moclobemide Social

- Phobia Clinical Study Group. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. *Int Clin Psychopharmacol* 2002; 17:161–170
52. Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. *Br J Psychiatry* 1998;172:70–77
  53. Pollack MH, Worthington JJ III, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. *Psychopharmacol Bull* 1996;32:667–670
  54. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. *Int Clin Psychopharmacol* 1999;14:239–245
  55. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. *J Clin Psychopharmacol* 1983;3:28–31
  56. Simon NM, Emmanuel N, Ballenger J, et al. Bupropion sustained release for panic disorder. *Psychopharmacol Bull* 2003;37:66–67
  57. Emmanuel NP, Brawman-Mintzer O, Morton WA, et al. Bupropion-SR in treatment of social phobia. *Depress Anxiety* 2000;12:111–113
  58. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. *J Clin Psychiatry* 1991;52:69–76
  59. Otto MW, Pollack MH, Gould RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. *J Anxiety Disord* 2000;14:345–358
  60. Gelernter CS, Uhde TW, Cimboric P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. *Arch Gen Psychiatry* 1991;48:938–945
  61. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. *Acta Psychiatr Scand* 1993;88: 1–11
  62. van Vliet IM, den Boer JA, Westenberg HG, et al. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. *J Clin Psychiatry* 1997;58:164–168
  63. Pande AC, Pollack MH, Crockett J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. *J Clin Psychopharmacol* 2000; 20:467–471
  64. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. *J Clin Psychopharmacol* 1999;19:341–348
  65. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. *Expert Opin Investig Drugs* 2003;12:663–672
  66. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. *J Clin Psychiatry* 1994;55:134–136
  67. Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. *Int Clin Psychopharmacol* 2003;18:169–172
  68. Ravaris CL, Friedman MJ, Hauri PJ, et al. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. *J Clin Psychopharmacol* 1997;11:344–350
  69. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. *J Clin Psychopharmacol* 1989;9:22–27
  70. Gorman JM, Levy GF, Liebowitz MR, et al. Effect of acute  $\beta$ -adrenergic blockade on lactate-induced panic. *Arch Gen Psychiatry* 1983;40: 1079–1082
  71. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. *Clin Psychol Rev* 1995;15:819–844
  72. Klein DF. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. *Am J Psychiatry* 2000;157:1204–1211
  73. Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. *J Behav Ther Exp Psychiatry* 1996;27:1–9